Home › Funds › Nextech Invest Ltd. › GLUE
Nextech Invest Ltd. position in GLUE
MONTE ROSA THERAPEUTICS INC · Health Care
Nextech Invest Ltd. reported holding 761,153 shares of GLUE (MONTE ROSA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$9.1M, representing 0.41% of its reported portfolio and ranking #14 among its reported holdings. Nextech Invest Ltd. has disclosed GLUE holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Nextech Invest Ltd.'s GLUE position evolved
Nextech Invest Ltd. first disclosed a stake in GLUE in Q4 2025 at 279,237 shares (US$4.4M). The position peaked in Q2 2026 at 761,153 shares, worth US$18.4M. Across 4 filings, Nextech Invest Ltd. increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 761,153 shares valued at US$9.1M. Notable position changes include a 150% increase in Q2 2026 (shares fell 51% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 279.24K | $4.38M | New |
| Q1 2026 | 304.24K | $5.00M | Add |
| Q2 2026 | 761.15K | $18.42M | Add |
| Q3 2026 | 761.15K | $9.08M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GLUE and 13F data
GLUE (MONTE ROSA THERAPEUTICS INC) is a Health Care company. 48 other funds we track also report a position in GLUE — the largest reported positions include Vestal Point Capital, LP (US$85.1M), NEA Management Company, LLC (US$79.8M), BAKER BROS. ADVISORS LP (US$51.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GLUE
- Vestal Point Capital, LP 7.13M sh · $85.06M · Q3 2026
- NEA Management Company, LLC 6.69M sh · $79.84M · Q3 2026
- BAKER BROS. ADVISORS LP 4.35M sh · $51.84M · Q3 2026
- BVF INC/IL 4.28M sh · $51.02M · Q3 2026
- TCG Crossover Management, LLC 3.78M sh · $45.11M · Q3 2026
- Versant Venture Management, LLC 3.18M sh · $37.95M · Q3 2026
- MONTANOVA CAPITAL, LLC 2.92M sh · $34.79M · Q3 2026
- BRAIDWELL LP 2.53M sh · $30.14M · Q3 2026
- Aisling Capital Management LP 1.56M sh · $18.56M · Q3 2026
- Opaleye Management Inc. 745.00K sh · $18.03M · Q2 2026
- MPM BioImpact LLC 1.13M sh · $13.42M · Q3 2026
- ADAR1 Capital Management, LLC 1.01M sh · $12.02M · Q3 2026
More on Nextech Invest Ltd.
FAQ
How long has Nextech Invest Ltd. held GLUE?
Nextech Invest Ltd. has disclosed GLUE holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Nextech Invest Ltd.'s current position in GLUE?
As of Q3 2026, Nextech Invest Ltd. holds 761.15K shares of GLUE (MONTE ROSA THERAPEUTICS INC), valued at $9.08M, representing 0.41% of its reported portfolio and ranking #14.
Has Nextech Invest Ltd. been buying or selling GLUE?
In the latest 13F filing (Q3 2026), Nextech Invest Ltd. held unchanged its position in GLUE. The position peaked in Q2 2026 at 761.15K shares.
Which other funds hold GLUE?
Other major institutional holders of GLUE include Vestal Point Capital, LP, NEA Management Company, LLC, BAKER BROS. ADVISORS LP, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.